News
ADYX
0.0001
0.00%
0.0000
NEXGEL to Host Fireside Chat with CEO Adam Levy on December 14th at 11:00 a.m. ET
NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today it will host a virtual fireside chat with its Chief Executiv...
PR Newswire · 12/01/2022 16:00
SAGE Journals Publishes New Data Revealing NEXGEL’s SilverSeal Hydrogel Dressing Improves Postsurgical Scarring
Patients Treated with SilverSeal Experienced Significantly Less Scarring and Improved Skin Functionality Following Surgical Incision LANGHORNE, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leadin...
GlobeNewswire · 10/03/2022 11:30
NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the C...
GlobeNewswire · 09/29/2022 11:30
NEXGEL to Report its Second Quarter 2022 Financial and Operating Results on August 10th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for...
GlobeNewswire · 08/04/2022 11:30
NEXGEL Launches MEDAGEL Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service
The Company's Proprietary Hydrogel Technology Protects Lower Lashes and Allows for Gentle Removal LANGHORNE, Pa., July 26, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-wa...
GlobeNewswire · 07/26/2022 11:30
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administra...
GlobeNewswire · 07/18/2022 11:05
NEXGEL and Partners for World Health Join Forces to Support Humanitarian Relief Efforts in Ukraine and Around the World
For Every Two Boxes of SilverSeal® Purchased, One is Donated to Those Suffering in Ukraine LANGHORNE, Pa., July 06, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-con...
GlobeNewswire · 07/06/2022 11:30
NEXGEL to Present at the LD Micro Invitational XII on June 8, 2022
Langhorne, Pennsylvania--(Newsfile Corp. - June 1, 2022) - NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW) ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced...
Newsfile · 06/01/2022 11:30
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members,...
GlobeNewswire · 05/16/2022 12:00
NEXGEL to Report its First Quarter 2022 Financial and Operating Results on May 12, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the fi...
PR Newswire · 05/09/2022 11:30
NEXGEL to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO of NEXGEL, will participate at the Planet...
PR Newswire · 04/28/2022 12:30
NEXGEL to Present at Maxim Group's 2022 Virtual Growth Conference
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participat...
PR Newswire · 03/24/2022 12:00
NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year periods...
PR Newswire · 03/21/2022 20:00
NEXGEL to Report its Fourth Quarter and Full Year 2021 Financial and Operating Results on March 21, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the four...
PR Newswire · 03/17/2022 12:30
NEXGEL Announces Launch of MEDAGEL Bug Bite Relief Patch
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL Bug Bite Relief Patch. These coolin...
PR Newswire · 02/15/2022 12:30
NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL ClearComfort Hydrogel Patch. The pa...
PR Newswire · 01/12/2022 12:30
NEXGEL Provides 2021 Year in Review
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetic, today is...
PR Newswire · 01/10/2022 12:30
NEXGEL to Present at H.C. Wainwright's Bioconnect Conference
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today a...
PR Newswire · 01/04/2022 13:00
NexGel, Inc. Announces Closing of $14.2 Million Initial Public Offering
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today a...
PR Newswire · 12/27/2021 18:16
Bucks County medical device developer goes public with $14.2M IPO
The company is the sixth local life sciences company to complete an initial public stock offering in 2021.
American City Business Journals · 12/23/2021 15:18
More
Webull provides a variety of real-time ADYX stock news. You can receive the latest news about Adynxx through multiple platforms. This information may help you make smarter investment decisions.
About ADYX
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.